adagrasib + pembrolizumab + pemetrexed + cisplatin + carboplatin

This regimen is a **combination therapy** consisting of the KRAS G12C inhibitor adagrasib, the PD-1 immune checkpoint inhibitor pembrolizumab, and the chemotherapeutic agents pemetrexed, cisplatin, and carboplatin. Adagrasib is a selective, covalent inhibitor of the KRAS G12C mutant protein, disrupting oncogenic signaling in tumors harboring this mutation. Pembrolizumab is a monoclonal antibody that blocks the interaction between PD-1 and its ligands, restoring T-cell mediated antitumor activity (immunotherapy). Pemetrexed is a multitargeted antifolate cytotoxic chemotherapy agent that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase, interfering with DNA and RNA synthesis. Cisplatin and carboplatin are platinum-based DNA crosslinking agents that inhibit DNA replication and transcription. This combination is under investigation for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation, typically in non-squamous histology and in patients with various PD-L1 expression levels[1][3][5].

Brand names

KeytrudaAlimtaPlatinolParaplatin

Other names

adagrasib + pembrolizumab + pemetrexed + cisplatin + carboplatin